ADYX — Adynxx Share Price
Last trade - 00:00- $0.00m
- $8.41m
- $2.22m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -1607.17% | ||
Financial Summary
| Year End 31st Dec | Unit | 2014 | 2015 | 2016 | 2017 | 2018 | 2019E | 2020E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.79 | 12.18 | 16.29 | 2.02 | 2.22 | n/a | n/a | 4.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Adynxx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to market disease-modifying products to address unmet needs in the treatment of pain and inflammation. The Company has leveraged its AYX platform of proprietary transcription factor decoys to identify and develop product candidates designed to modify the course of pain. Its product pipeline includes Brivoligide for postoperative pain and AYX2 for chronic pain. Brivoligide is a transcription factor decoy specifically designed to inhibit the function of transcription factor Early Growth Response 1 (EGR1), in the dorsal root ganglia (DRG), and spinal cord when administered at the time of surgery. Its second product candidate, AYX2, is a transcription factor decoy targeting the activity of specific members of the KLF family of transcription factors, including KLF6, KLF9 and KLF15.
Directors
- Dennis Podlesak CHM (63)
- Rick Orr CEO
- Julien Mamet CSO
- Donald Manning OTH (62)
- Stan Abel DRC
- Gregory Flesher DRC (49)
- Matthew Ruth DRC
- Eckard Weber DRC
- Last Annual
- December 31st, 2018
- Last Interim
- September 30th, 2019
- Incorporated
- April 15th, 2014
- Public Since
- October 12th, 1998
- No. of Shareholders
- 5,005,211
- No. of Employees
- 6
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 5,807,877
- Address
- 100 Pine St Ste 500, SAN FRANCISCO, 94111-5103
- Web
- https://ir.adynxx.com/
- Phone
- +1 4155127740
- Auditors
- Marcum LLP
Upcoming Events for ADYX
Similar to ADYX
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Aeolus Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 18:05 UTC, shares in Adynxx are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Adynxx last closed at $0.00 and the price had moved by -99% over the past 365 days. In terms of relative price strength the Adynxx share price has underperformed the S&P500 Index by -99.18% over the past year.
The overall consensus recommendation for Adynxx is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAdynxx does not currently pay a dividend.
Adynxx does not currently pay a dividend.
Adynxx does not currently pay a dividend.
To buy shares in Adynxx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Adynxx had a market capitalisation of $0.00m.
Here are the trading details for Adynxx:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ADYX
Based on an overall assessment of its quality, value and momentum Adynxx is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Adynxx is $2.80. That is 279999900% above the last closing price of $0.00.
Analysts covering Adynxx currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Adynxx. Over the past six months, its share price has underperformed the S&P500 Index by -7.99%.
As of the last closing price of $0.00, shares in Adynxx were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Adynxx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Adynxx's management team is headed by:
- Dennis Podlesak - CHM
- Rick Orr - CEO
- Julien Mamet - CSO
- Donald Manning - OTH
- Stan Abel - DRC
- Gregory Flesher - DRC
- Matthew Ruth - DRC
- Eckard Weber - DRC